SCHEMBL27384648

SCHEMBL27384648

CC(C)c1cc2[nH]c(CNC(=O)N3CCC3)cc2cc1F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EIF4A3 P38919 1/20 0.48
▸ MAPK1 P28482 5/20 0.41
▸ RAB9A P51151 2/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ CASP1 P29466 1/20 0.34
▸ CASP7 P55210 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ HTR2C P28335 1/20 0.33
▸ HTR2B P41595 1/20 0.33
▸ HRH3 Q9Y5N1 1/20 0.33
▸ METTL3 Q86U44 2/20 0.33
▸ METTL14 Q9HCE5 2/20 0.33
▸ EPHX2 P34913 1/20 0.33
▸ CYP1A2 P05177 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27384655 0.98 EIF4A3 (0.48) EIF4A3MAPK1RAB9ANPC1SMN1; SMN2
SCHEMBL27384340 0.97 EIF4A3 (0.47) EIF4A3MAPK1RAB9ANPC1SMN1; SMN2
SCHEMBL27384342 0.89 EIF4A3 (0.42) EIF4A3MAPK1RAB9ANPC1SMN1; SMN2
SCHEMBL27384352 0.87 EIF4A3 (0.49) EIF4A3MAPK1RAB9ANPC1SMN1; SMN2
SCHEMBL27384348 0.87 EIF4A3 (0.46) EIF4A3MAPK1RAB9ANPC1SMN1; SMN2
SCHEMBL27384264 0.86 MAPK1 (0.40) EIF4A3MAPK1RAB9ANPC1SMN1; SMN2
SCHEMBL27384339 0.85 MAPK1 (0.42) EIF4A3MAPK1RAB9ANPC1SMN1; SMN2
SCHEMBL27384854 0.84 MAPK1 (0.41) MAPK1RAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL27384336 0.84 MAPK1 (0.40) MAPK1RAB9ASMN1; SMN2KDM4EMEN1
SCHEMBL27382678 0.82 EIF4A3 (0.56) EIF4A3RAB9ANPC1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024081748-A2 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF MAZE THERAPEUTICS, INC. (US) 2024-04-18 — — WO disclosed
Send feedback